Aperio Group LLC grew its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 15.1% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 56,732 shares of the life sciences company’s stock after purchasing an additional 7,426 shares during the period. Aperio Group LLC’s holdings in Illumina were worth $12,395,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Advisory Services Network LLC lifted its position in Illumina by 13.0% during the 2nd quarter. Advisory Services Network LLC now owns 772 shares of the life sciences company’s stock valued at $134,000 after acquiring an additional 89 shares during the period. Dupont Capital Management Corp purchased a new position in Illumina during the 3rd quarter valued at about $153,000. Mitsubishi UFJ Securities Holdings Co. Ltd. lifted its position in Illumina by 113.9% during the 4th quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 770 shares of the life sciences company’s stock valued at $168,000 after acquiring an additional 410 shares during the period. Patten Group Inc. lifted its position in Illumina by 71.1% during the 3rd quarter. Patten Group Inc. now owns 1,480 shares of the life sciences company’s stock valued at $172,000 after acquiring an additional 615 shares during the period. Finally, Riverbridge Partners LLC purchased a new position in Illumina during the 4th quarter valued at about $202,000. 92.09% of the stock is currently owned by hedge funds and other institutional investors.

Illumina, Inc. (NASDAQ ILMN) opened at $209.54 on Friday. The company has a quick ratio of 3.55, a current ratio of 3.99 and a debt-to-equity ratio of 0.42. The stock has a market cap of $30,590.00, a PE ratio of 42.50, a price-to-earnings-growth ratio of 2.92 and a beta of 0.92. Illumina, Inc. has a twelve month low of $158.02 and a twelve month high of $248.97.

Illumina (NASDAQ:ILMN) last issued its earnings results on Tuesday, January 30th. The life sciences company reported $1.44 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.22 by $0.22. The business had revenue of $778.00 million during the quarter, compared to analysts’ expectations of $752.04 million. Illumina had a net margin of 26.56% and a return on equity of 21.52%. The business’s revenue for the quarter was up 25.7% compared to the same quarter last year. During the same period in the previous year, the company earned $0.85 earnings per share. sell-side analysts predict that Illumina, Inc. will post 4.59 EPS for the current fiscal year.

In other news, SVP Oene Mark Van sold 1,232 shares of the business’s stock in a transaction that occurred on Monday, November 13th. The shares were sold at an average price of $207.78, for a total transaction of $255,984.96. Following the completion of the transaction, the senior vice president now directly owns 11,691 shares of the company’s stock, valued at $2,429,155.98. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Charles Dadswell sold 145 shares of the business’s stock in a transaction that occurred on Monday, December 4th. The shares were sold at an average price of $225.33, for a total transaction of $32,672.85. Following the transaction, the senior vice president now directly owns 6,388 shares of the company’s stock, valued at $1,439,408.04. The disclosure for this sale can be found here. Insiders have sold 118,922 shares of company stock valued at $26,245,549 over the last three months. 0.89% of the stock is owned by corporate insiders.

A number of brokerages recently issued reports on ILMN. Wells Fargo & Co reissued a “market perform” rating and set a $205.00 price target (up from $200.00) on shares of Illumina in a research report on Wednesday, October 25th. BidaskClub cut shares of Illumina from a “buy” rating to a “hold” rating in a research report on Saturday, February 3rd. Zacks Investment Research raised shares of Illumina from a “hold” rating to a “buy” rating and set a $252.00 price target for the company in a research report on Tuesday, December 5th. Bank of America lifted their price target on shares of Illumina from $215.00 to $240.00 and gave the company a “buy” rating in a research report on Wednesday, October 25th. Finally, Morgan Stanley lifted their price target on shares of Illumina from $122.00 to $135.00 and gave the company an “underweight” rating in a research report on Thursday, December 14th. One analyst has rated the stock with a sell rating, eight have issued a hold rating and fourteen have issued a buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $241.39.

TRADEMARK VIOLATION WARNING: This article was originally published by Daily Political and is the property of of Daily Political. If you are viewing this article on another publication, it was illegally copied and reposted in violation of United States and international copyright & trademark laws. The original version of this article can be read at https://www.dailypolitical.com/2018/02/09/aperio-group-llc-increases-stake-in-illumina-inc-ilmn.html.

Illumina Profile

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.